BSE Live
Oct 17, 16:01Prev. Close
1240.05
Open Price
1240.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 17, 15:57Prev. Close
1240.20
Open Price
1245.00
Bid Price (Qty.)
1255.90 (102)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 32,553.50 | 27,916.40 | 24,587.90 | 21,439.10 | 18,972.20 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 32,553.50 | 27,916.40 | 24,587.90 | 21,439.10 | 18,972.20 | |
Total Operating Revenues | 32,643.90 | 28,011.10 | 24,669.70 | 21,545.20 | 19,047.50 | |
Other Income | 1,097.30 | 894.30 | 1,055.50 | 484.40 | 291.40 | |
Total Revenue | 33,741.20 | 28,905.40 | 25,725.20 | 22,029.60 | 19,338.90 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 5,683.50 | 4,490.10 | 4,219.80 | 4,312.40 | 4,295.80 | |
Purchase Of Stock-In Trade | 4,841.10 | 4,399.10 | 3,367.00 | 3,483.70 | 2,573.60 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | -544.70 | -680.50 | 70.90 | -353.90 | -790.50 | |
Employee Benefit Expenses | 5,580.00 | 5,030.10 | 4,646.60 | 3,885.80 | 3,629.90 | |
Finance Costs | 282.90 | 171.10 | 142.80 | 95.80 | 97.00 | |
Depreciation And Amortisation Expenses | 1,703.70 | 1,470.00 | 1,250.20 | 1,165.20 | 1,228.80 | |
Other Expenses | 8,367.60 | 6,838.90 | 5,946.50 | 5,519.10 | 4,792.00 | |
Total Expenses | 26,083.40 | 21,719.10 | 19,713.70 | 19,038.50 | 16,503.40 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 7,657.80 | 7,186.30 | 6,011.50 | 2,991.10 | 2,835.50 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 7,657.80 | 7,186.30 | 6,011.50 | 2,991.10 | 2,835.50 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 2,258.10 | 1,945.90 | 814.40 | 1,101.30 | 817.20 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -303.80 | -322.80 | 726.80 | -222.40 | 114.70 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 1,954.30 | 1,623.10 | 1,541.20 | 878.90 | 931.90 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 5,703.50 | 5,563.20 | 4,470.30 | 2,112.20 | 1,903.60 | |
Profit/Loss From Continuing Operations | 5,703.50 | 5,563.20 | 4,470.30 | 2,112.20 | 1,903.60 | |
Profit/Loss For The Period | 5,703.50 | 5,563.20 | 4,470.30 | 2,112.20 | 1,903.60 | |
Minority Interest | -70.10 | 0.00 | 0.00 | 0.00 | 0.00 | |
Consolidated Profit/Loss After MI And Associates | 5,655.10 | 5,577.90 | 4,507.30 | 2,182.50 | 1,951.60 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 68.00 | 335.00 | 271.00 | 132.00 | 118.00 | |
Diluted EPS (Rs.) | 68.00 | 335.00 | 271.00 | 131.00 | 117.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 666.20 | 664.80 | 497.90 | 414.60 | 414.70 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
17.09.2025
15.09.2025
11.09.2025
28.08.2025
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
23.07.2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs 1,418 crore, revenue up 11%
12.05.2025
Dr Reddys Labs Standalone March 2025 Net Sales at Rs 5,562.90 crore, up 8.97% Y-o-Y
12.05.2025
Dr Reddys Labs Consolidated March 2025 Net Sales at Rs 8,528.40 crore, up 19.89% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz